Carto-Merge技术指导下肺静脉前庭电解剖隔离的初期经验

目的:介绍应用Carto-Merge技术将左心房和肺静脉CT三维重建图像与Carto电解剖标测图像相整合,指导肺静脉前庭电解剖隔离治疗心房颤动的初期经验.方法:对13例阵发性和2例持续性房颤患者,应用Carto-Merge技术进行肺静脉前庭电解剖隔离.结果:消融前左心房各壁标测点为(103±13)个;图像融合后,点与面之间的配准距离为(1.8±0.2) mm;环左肺静脉消融点(66±15)个,环右肺静脉消融点(58±20)个;所有患者均达到肺静脉电隔离;手术时间(305±45) min,透视时间(52±18) min;术中、术后无并发症发生.结论:CT三维重建后的图像接近真实解剖,与Carto电解剖标测图像的整合图像可帮助术者校正和弥补Carto电解剖图像的不足,有助于提高手术成功率,减少并发症.     

肺静脉口节段性电隔离和环肺静脉消融治疗阵发性房颤的比较

目的 比较肺静脉口节段性电隔离（SPVI）和环肺静脉消融（CPVA）两种术式治疗阵发性房颤在方法学、疗效和安全性方面的差异。方法 66例阵发性房颤患者30例接受SPVI术,36例CPVA术,两组患者一般临床情况相似。。SPVI组经验性电隔离四条肺静脉。CPVA组采用CARTO电解剖标测系统及双Lasso标测电极技术,分别进行环左、右侧肺静脉线性消融,消融终点为肺静脉电隔离。记录方法学参数：手术时间、射频放电时间、X线曝光时间。术前和术后检查超声心动图、动态心电图和左房及肺静脉螺旋CT三维重建。结果 SPVI组的手术时间（137±36）min ,放电时间（36±10）min,与CPVA组手术时间（208±61）min,放电时间（76±17）min比较差异有显著性（P<0.05）,而X线曝光时间（40±13）min）,与CPVA组（46±20）min相似（P=0.113）。术后随访（407±150）d,SPVI组和CPVA组手术达到终点率（93% vs. 86% P =0.343）和治愈率（70% vs. 75% P=0.650）相似。总的并发症发生率无显著性差异（13% vs. 8%, P=0.511）。SPVI组3例,而CPVA组无肺静脉狭窄并发症;CPVA组2例脑梗死,而SPVI组无。两组各出现1例心包填塞。结论 CPVA术治疗阵发性房颤的疗效和安全性与SPVI术相似,而手术时间、放电时间较长。     

肺静脉节段性隔离与环肺静脉隔离导管消融治疗心房颤动的初步比较

目的 比较肺静脉节段性隔离(SPVI)与EnSiteNavX三维电生理系统指导下环肺静脉隔离导管消融(CPVA)治疗心房颤动的有效性与安全性.方法 入选共85例房颤患者,单纯肺静脉环状电极指导下行肺静脉节段性隔离40例(阵发性30例,持续性10例);EnSiteNavX三维电生理系统指导下环肺静脉隔离45例(阵发性31例,持续性14例),随访均超过半年.结果 SPVI组成功率为65%,CPVA组成功率为84.4%,P=0.038.主要并发症发生率SPVI组为17.5%,CPVA组为6.7%,P=0.0845;肺静脉狭窄率在CPVA组为0%,在SPVI组为12.5%,P=0.0312.总手术操作时间在SPVI组为(200.4±37.0)min,在CPVA组为(226.5±26.1)min,P=0.002.X线曝光时间在SPVI组为(54.7±9.7)min,在CPVA组为(27.1±3.1)min,P<0.0001.结论 EnSiteNavX三维电生理系统指导下环肺静脉隔离导管消融治疗房颤较单纯肺静脉环状电极指导下的节段性肺静脉隔离更为有效且X线曝光时间更短,但手术操作时间较长;主要并发症发生率在两组间无明显差异,但环肺静脉隔离组的肺静脉狭窄率较节段性隔离组低.     

导管消融治疗心房颤动的有效性与安全性研究

目的探讨经导管消融治疗心房颤动的有效性和安全性。方法对32例阵发性房颤,4例持续性房颤患者进行导管消融治疗。其中,3例患者采用环状冷冻导管消融(cryoablation)隔离肺静脉;33例患者采用Lasso导管及三维电解剖标测(CARTO)指导的环肺静脉前庭线性消融。结果成功率:冷冻消融组为33.33%;CARTO组为90.9%。手术时间:CARTO组较冷冻消融组,手术时间延长,CARTO组手术时间为(325±79)min;冷冻消融(205±72)min,P<0.05。X线曝光时间:CARTO组较冷冻消融组,曝光时间缩短,CARTO组(43±16)min;冷冻消融为(55±18)min,P<0.05。并发症:冷冻消融无并发症;CARTO组出现2例心脏压塞;另有1例患者术后第2d出现脑栓塞,经药物治疗后,肢体障碍完全恢复。结论经导管冷冻消融及CARTO指导下,环肺静脉前庭线性消融治疗房颤的方法均安全有效。三维电解剖标测(CARTO)指导下的环肺静脉前庭线性消融术效果更好。     

电解剖标测系统加单环状电极导管指导环肺静脉前庭线性消融电隔离肺静脉治疗心房颤动

目的 探讨电解剖标测系统(CARTO)加单Lasso导管指导下行环肺静脉前庭线性消融电隔离肺静脉治疗心房颤动(房颤)的初步经验. 方法 3例房颤患者接受治疗,其中阵发性房颤2例,持续性房颤1例.所有患者首先用CARTO系统进行左房重建,然后将一根Lasso导管置入肺静脉内,在肺静脉口外5～10 mm处行环肺静脉前庭线性消融,消融终点为双侧肺静脉完全电隔离. 结果 3例患者均成功达到消融终点,手术时间(205±46)min,X线透视时间(46±13)min.手术过程中无并发症发生.术后随访7个月,3例患者均未再发房颤,均无出现肺静脉狭窄. 结论 在CARTO加单Lasso导管指导下行环肺静脉前庭线性消融电隔离肺静脉治疗房颤安全有效.     

三维电解剖标测指导环肺静脉线性消融治疗阵发性心房颤动

目的 探讨在Carto三维电解剖标测指导左心房环肺静脉线性消融治疗阵发性心房颤动的疗效。方法 对2例入选的阵发性房颤患者使用Carto系统建立左心房三维电解剖图,结合肺静脉造影确定肺静脉开口,围绕左、右上、下肺静脉口完成环肺静脉线性消融。预设温度43℃,最大功率30w,每点消融时间大于20s。局部电位振幅降低50％以上再移动靶点,逐点完成预定消融线。结果 2例患者操作时间分别为181min和193min,透视时间为60min和78min,放电次数120次和136次。术后随访8个月和1个月。例2在术后第3天再发房颤,但1个月内次数较前明显减少。2例患者均无肺静脉狭窄发生。结论 三维电解剖标测指导在左心房环肺静脉线性消融治疗阵发性房颤安全有效。     

三维电解剖标测系统联合CT影像融合技术指导心房颤动环肺静脉电隔离术的临床研究

目的探讨和比较新型三维电解剖标测系统(CARTO3)及CT影像融合技术(CARTO-Merge)指导阵发性心房颤动与持续性心房颤动环肺静脉电隔离术(CPVI)的有效性和安全性。方法 52例经药物治疗无效且有房颤症状患者分为阵发性房颤组24例(A组)与持续性房颤组28例(B组)。将术前16排心脏CT扫描数据与CARTO3系统快速解剖标测重建三维解剖图形进行CARTO-Merge融合,指导CPVI,终点为消除所有肺静脉电位,未转律者行直流电复律。结果所有患者用环状标测导管Lasso建模,A组与B组间肺静脉前庭平均直径、平均手术总时间及平均冷盐水输入量差异均有统计学意义(均<0.05);两组CARTO三维消融靶点图与CT三维解剖图的平均距离、平均融合时间、平均X线曝光及消融时间差异均无统计学意义(均>0.05)。A组18例(75%)与B组14例(50%)患者消融转为窦律,两组均未发生严重并发症。结论 CARTO3及CARTO-Merge指导房颤CPVI具有较好的有效性与安全性。     

非接触三维标测系统指导下环肺静脉电隔治疗心房颤动的临床评价

目的:探讨非接触三维标测系统指导下环肺静脉电融隔离治疗心房颤动(房颤)的可行性和临床疗效.方法:28例药物治疗无效或不能耐受的房颤患者.其中23例阵发性房颤、5例持续性房颤.采用非接触三维标测系统(Ensite navX)建立左心房、肺静脉的三维等时电势图和电解剖图,并在距离肺静脉口1～2 cm处行环肺静脉及其周围组织电隔离.消融终点包括:完成所有环肺静脉消融径线;全部肺静脉均达电隔离;阴性诱发结果.结果:28例患者均达到消融终点;手术的总操作时间和X线曝光时间分别为(161.3±23.2)min和(38.0±6.8)min;随访6～17月,20例(71%)无房颤发作;8例(29%)有房颤复发,其中2例因其发作次数及时间均较术前明显减少未再消融,予以可达龙治疗可控制(术前可达龙治疗无效),6例行第2次消融,术中均发现肺静脉电位有不同程度的恢复,第2次术后4例房颤无再发,2例仍有发作但未再消融,予以可达龙治疗可控制.术中及随访期间无任何操作相关并发症.结论:非接触三维标测系统指导下的环肺静电隔离是治疗房颤的有效而安全的方法.肺静脉既是房颤的诱发机制,亦有可能参与房颤的维持.     

环肺静脉加辅助径线消融治疗持续性和永久性心房颤动

目的 评估环肺静脉加辅助径线消融治疗持续性和永久性心房颤动(房颤)的有效性和安全性,分析房颤消融后复发的危险因素.方法 通过多中心临床注册研究的方式收集全国2006年1月至2006年12月期间行环肺静脉加辅助径线消融治疗持续性和永久性房颤的127例病例资料,分析环肺静脉加辅助径线消融治疗持续性和永久性房颤的成功率和复发率,对心脏功能和房性心律失常的影响,以及并发症发生情况.将临床和超声影像学指标作为待选变量,探讨消融后房颤复发的危险凶素.结果 在平均(94±4)个月随访期间,成功率为68.5%,复发率为31.5%.消融成功的患者术后左心房内径[(41±8)mm vs(43±7)mm]、左心室舒张末期直径[(49±7)mm vs(48±6)mm]和左心室射血分数[(61±8)%vs(62±10)%]较术前无明显改变(均P>0.05).消融后房性心动过速和房性早搏有所增加(P<0.05和P<0.01).消融并发症为皮下血肿3例(2.4%).与复发相关的危险因素有女性(P<0.05)和左心房增大(P<0.05).结论 环肺静脉加辅助径线消融治疗持续性和永久性心房颤动安全性好,具有较好的有效性.     

环肺静脉电隔离术与递进式个体化心房基质消融术治疗房颤结果对照

目的 观察比较环肺静脉电隔离术(CPVI)与递进式个体化心房基质消融术(SSCA)的疗效与安全性.方法 连续入选62例阵发性房颤患者,随机分为CPVI组(38例)及SSCA组(24例)；术中采用CARTO和Lasso环状标测电极导管指导消融；术后对患者定期进行体表心电图与动态心电图检查,比较两者的X线曝光时间、手术时间、未复发率等.结果 CPVI组和SSCA组的X线曝光时间分别为(33.32±6.03)min和(33.42±3.93)min,手术时间分别为(125.66±11.78)min和(131.13±10.47)min,两者对比无统计学意义(P＞0.05)；两组6个月随访时的未复发率分别为86.8％和62.5％,CPVI组高于SSCA组(x2=4.986,P＜0.05).结论 在远期未复发率方面,CPVI似乎更有优势,但还需进一步观察、随访；提高房颤治愈率的根本在于对房颤机制研究的突破.     

EnSite NavX三维电生理系统指导下环肺静脉前庭隔离导管消融治疗心房颤动

目的 探讨EnSire NavX三维电生理系统指导环肺静脉前庭隔离导管消融治疗心房颤动(房颤)的有效性和安全性.方法 在EnSite NavX三维电生理系统指导下对38例药物治疗无效的阵发性或持续性房颤患者行环肺静脉导管消融,随访观察其疗效和安全性.结果 38例患者都达到消融终点,双侧肺静脉均完全隔离.手术操作时间(233.8±31.7)min,X线曝光时间(32.5±4.7)min,左房建模时间(27.5±7.5)min.术后随访(9±3)月,单次消融的成功率为89.5%,出现并发症7.9%.结论 EnSite NavX三维电生理系统指导下环肺静脉前庭隔离导管捎融治疗房颤是一种较为有效且安全的方法.     

以环肺静脉消融为基础分步消融治疗心房颤动

目的探讨在三维标测系统指导下，以环肺静脉消融为基础，分步消融治疗心房颤动（房颤）的可行性和有效性。方法对12例药物治疗无效的阵发性房颤（10例）和持续性房颤（2例）患者，以三步消融方法进行消融：环肺静脉前庭消融、节段性肺静脉消融和碎裂电位 (CFAEs) 消融。以每个阶段房颤不再被诱发作为消融终点,或完成三个阶段。结果消融结束时，10例阵发性房颤不再被诱发，其中第1阶段7例，第2阶段2例，第3阶段1例。2例持续性房颤在完成所有3个阶段后仍持续发作，最后经体外电转复。3例于术后2d内短暂复发，继续随访后未再房颤复发，1例房颤并典型心房扑动（房扑）患者术后复发房扑，无房颤复发。所有患者经(10±4)个月随访后，均无房颤复发，无左房房性心律失常出现。手术无并发症发生。手术中放电时间(38±11)min, X线透视时间(37±11)min，操作时间(3.0±0.5)h。结论 以房颤不再被诱发为手术终点、以环肺静脉消融为基础的分步消融治疗房颤策略是安全可行的。对于阵发性房颤采用环肺静脉消融术式即有良好效果，而对单纯环肺静脉消融不成功者结合节段性肺静脉消融及碎裂电位消融可进一步提高成功率。     

Recurrent atrial tachycardia and atrial fribrillation after circumferential pulmonary vein ablation: What's the difference?

Background Recurrent atrial tachyarrhythmia (ATa) after circumferential pulmonary vein ablation (CPVA) includes atrial tachycardia (AT) and atrial fribrillation (AF). However, whether there are some differences in clinical course and mechanisms between the recurrent AT and the recurrent AF remained unclear. This study was conducted to investigate the incidence, mechanism, clinical course of the recurrent AT and AF in patients under CPVA.Methods One hundred and thirty consecutive patients (M/F=95/35) with highly symptomatic and multiple antiarrhythmic drugs (AADs) refractory paroxysmal (n=91) or persistent (n=39) AF were included. The ablation protocol consisted solely of two continuous circular lesions around the ipsilateral pulmonary veins (PV) guided by CARTO system. The endpoint of CPVA is PV isolation. For patients with recurrent ATa within 2 months after the initial procedure, cardioversion with direct current was attempted if the ATa lasted for more than 24 hours. A repeat ablation procedure was performed only for patients with AADs refractory recurrent ATa and at least followed up for 2 months after the initial procedure.Results Within 2 months after the initial procedure, 52 patients (40.0%) had experienced episodes of symptomatic recurrent ATa. Among them, 23 patients (44.2%) with recurred AT alone (AT group), 14 patients (26.9%) with recurred AF alone (AF group), and 15 patients (28.8%) with recurred AT and AF (AT plus AF group). The delayed cure rate (65.2%) in AT group was significant higher than that in AF group (21.4%, P<0.05) and AF plus AT group (26.7%, P<0.05). A repeat ablation was performed in 21 patients, including 6 patients with recurrent AT alone, 8 patients with recurrent AF alone, and 7 patients with recurrent AF plus AT. The mean number of PV gaps was 1.2±0.4 in AT group, which was significantly lower than that in AF group (2.6±0.7, P<0.05) and AF plus AT group (2.0±0.6, P<0.05). Delayed cure rate and number of PV gaps between AF group and AF plus AT group were comparable (P>0.05).Conclusions Present study indicates that recurrent AT and AF after CPVA have the different clinical course and different electrophysiological findings during repeat procedure as follows: ⑴After CPVA, spontaneous resolution of recurrent ATa was mainly found in patients with recurrent AT alone (about two thirds patients). ⑵The type of recurrent ATa after CPVA is associated with the number of PV gaps.     

Impact of right upper pulmonary vein isolation on atrial vagal innervation and vulnerability to atrial fibrillation

Background Based on the hypothesis that pulmonary vein isolation could result in the damage of the epicardial fat pads, this study aimed to investigated the impact of right upper pulmonary vein (RUPV) isolation on vagal innervation to atria. Methods Bilateral cervical sympathovagal trunks were decentralized in 6 dogs. Metoprolol was given to block sympathetic effects. Multipolar catheters were placed into the right atrium (RA) and coronary sinus (CS). RUPV isolation was performed via transseptal procedure. Atrial effective refractory period (ERP), vulnerability window (VW) of atrial fibrillation (AF), and sinus rhythm cycle length (SCL) were measured at RA and distal coronary sinus (CSd) at baseline and vagal stimulation before and after RUPV isolation. Serial sections of underlying tissues before and after ablation were stained with haematoxylin and eosin.Results SCL decreased significantly during vagal stimulation before RUPV isolation (197±21 vs 13±32 beats per minute,P&lt;0.001), but remained unchanged after RUPV isolation (162±29 vs 140±39 beats per minute, P&gt;0.05). ERP increased significantly before RUPV isolation compared with that during vagal stimulation [(85.00±24.29) ms vs (21.67±9.83) ms at RA, P&lt;0.001; (90.00±15.49) ms vs (33.33±25.03) ms at CSd P&lt;0.005], but ERP at baseline hardly changed after RUPV isolation compared with that during vagal stimulation [(103.33±22.50) vs (95.00±16.43) ms at RA, P = 0.09; (98.33±24.83) vs (75.00±29.50) ms at CSd, P=0.009]. The ERP shortening during vagal stimulation after RUPV isolation decreased significantly [(63.33±22.51) ms vs (8.33±9.83) ms at RA, P&lt;0.005; (56.67±20.66) ms vs (23.33±13.66) ms at CSd, P&lt;0.05]. AF was rarely induced at baseline before and after RUPV isolation (VW close to 0), while VW of AF to vagal stimulation significantly decreased after RUPV isolation [(40.00±10.95) vs 0 ms at RA, P&lt;0.001; (45.00±32.09) vs (15.00±23.45) ms at CS, P &lt;0.05]. The architecture of individual ganglia was significantly altered after ablation.Conclusions The less ERP shortening to vagal stimulation and altered architecture of individual ganglia after right upper pulmonary vein isolation indicate that isolation may result in damage of the epicardial fat pads, thereby attenuating the vagal innervation to atria. The decreased vulnerability window of atrial fibrillation indicates that vagal denervation may contribute to its suppression.     

房颤患者环肺静脉电隔离术后快速性房性心律失常的再消融治疗效果分析

目的:观察心房颤动患者环肺静脉电隔离术(CPVI)后快速性房性心律失常(ATa)的再消融治疗效果,并探讨其可能的发生机制。方法:64例阵发性房颤患者在初次行CPVI后(3.7±2.4)个月再次行电解剖标测系统指导下ATa标测和消融。结果:共标测到78种ATa,其中48种(61.5%)为局灶性机制,30种(38.5%)折返机制。在折返机制中,12例为普通房扑,18例为左房内折返,其折返环与二尖瓣峡部、左房前壁及原环肺静脉消融线上的传导间隙有关。2例患者因ATa不稳定而无法标测。64例患者中,56例(87.5%)消融即刻成功,8例需要电复律成窦性心律。术后随访13~21个月,平均(16.5±2.9)个月,60例(93.8%)患者不再发生ATa。结论:CPVI术后ATa的机制可为折返性和局灶性,可通过CARTO系统激动顺序标测成功消融治疗。     

Combined use of three-dimensional rotational angiogram of left atrium and circular multi-electrode ablation catheter for pulmonary vein isolation

Background  A novel circular pulmonary vein ablation catheter (PVAC) has been introduced for pulmonary vein isolation (PVI). Accurate delineation of left atrium-pulmonary vein (LA-PV) anatomy is important for this technique. The aim of this study was to test whether the 3-dimensional rotational angiography (3D RTA) of the left atrium can facilitate PVI using PVAC technique.

Methods  Twenty patients with paroxysmal atrial fibrillation (AF) were enrolled in this study. The 3D RTA was reconstructed and registered[L1]  with live fluoroscopy in all the patients. AF ablation was performed with a PVAC catheter in the navigation of registered 3D RTA.

Results  The 3DRTA image was successfully reconstructed and registered with live fluoroscopy in all patients (100%). The LA-PV anatomy was delineated clearly in all patients. Navigation of the PVAC inside the registered 3D RTA, ensured accurate placement within the atrium to perform ablation, and the PVAC was correctly placed inside the PV ostium to verify the PVI. All the PVs were isolated. Total procedural time was (87.5±12.1) minutes, and fluoroscopy time was (20.1±6.3) minutes. Follow-up after (7.1±1.5) months showed freedom from AF in 70% (14/20) patients. No PV stenosis was observed.

Conclusions  Intraprocedure reconstructed and registered 3D RTA can clearly delineate the LA-PV anatomy in real-time. The results demonstrate the feasibility and reliability of combining use of 3DRA and PVAC in AF ablation procedures.

 

     

Pulmonary vein tachycardia after pulmonary vein isolation in patients with atrial fibrillation

Background Pulmonary vein (PV) isolation has been developed to treat patients with atrial fibrillation (AF), and the electrophysiological endpoint of PV isolation is the disappearance or dissociation of pulmonary vein potentials (PVPs). Pulmonary vein tachycardia (PVT) is the dissociated PV rhythm with a rapid rate. However, the characteristics and significance of PVT after pulmonary vein isolation in patients with AF remains unclear. Methods From June 2003 to June 2005, a total of 285 consecutive patients with drug refractory AF were included in this study, and they underwent segmental pulmonary vein ablation (SPVA) or circumferential pulmonary vein ablation (CPVA). PV isolation was the initial endpoint for both approaches with documenting disappearance or dissociation of PVPs. PVT was characterized as dissociated activities within PVs with a circle length (CL) of &lt;300 ms, and was classified into organized PVT or disorganized PVT according to the variance of CL. Systematic follow-up was conducted after initial procedures. Continuous variables were analyzed by Student’s t test and categorical variables were analyzed by chi-square test.Results Three hundred and fifteen PVs were ablated in 85 patients underwent SPVA approach, 400 circular lesions surrounding ipsilateral PVs (including 790 PVs) were produced in the rest of 200 patients received CPVA approach. Electrical isolation was achieved in all of these PVs. Of these, PVPs were abolished in 89.8% (992/1105) of the ablated PVs, dissociated PV rhythms were documented in the rest 10.2 % (113/1105) of the treated PVs. Among the 113 dissociated PV rhythms, 28 met the criteria of PVT with mean CL of (155±43) ms (2 PVTs in 2 patients received SPVA, 26 PVTs in 18 patients underwent CPVA). PVT was more frequently documented in patients underwent CPVA approach [9.0% (18/200) vs 2.3% (2/85), P=0.04]. During the 6-month follow-up, it was indicated that no significant difference existed in AF free rate between patients with PVT and those without PVT (P=0.75). Conclusions PVT dissociated from LA activations can be documented after PV isolation, especially in patients underwent CPVA approach. However, PVT does not affect the follow-up results.     

盐酸右美托咪定复合靶控输注丙泊酚用于肝癌射频消融治疗的临床观察

目的：探讨盐酸右美托咪定复合靶控输注丙泊酚在肝癌射频消融术中应用的有效性及安全性。方法选择射频消融治疗肝癌患者60例,ASAⅠ～Ⅱ级,随机分为3组,每组20例：Ⅰ组（盐酸右美托咪定组）、Ⅱ组（靶控输注丙泊酚组）、Ⅲ组（盐酸右美托咪定+靶控输注丙泊酚组）。记录治疗开始前、治疗开始后5 min、结束即刻、出室时患者的心率（HR）、平均动脉压（MAP）、呼吸频率（RR）、脉搏血氧饱和度（SpO2）,同时记录苏醒时间、不良反应发生率、医生满意度评分。结果Ⅱ组治疗开始后5 min MAP[（69±8）mmHg]、HR[（69±3）次/min]、RR[（16±5）次/min]、SpO2[（90±4）%]与治疗前相比均明显降低（P<0.05）。Ⅲ组的苏醒时间显著短于Ⅱ组[（1.1±0.1）min vs.（3.1±0.2）min,P<0.05],Ⅲ组的医生满意度评分明显高于Ⅰ组与Ⅱ组（3.8±0.3 vs.1.9±0.3、2.0±0.6,P<0.05）。Ⅲ组呼吸暂停的发生率（0%）及低血压的发生率（5%）也明显低于Ⅱ组（20%、35%,P<0.05）。结论盐酸右美托咪定复合靶控输注丙泊酚用于超声引导下射频消融治疗肝癌安全可靠,患者术中循环呼吸平稳,苏醒快,医生满意度高。